Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in...

Area of Science:

• Hematology
• Oncology
• Infectious Diseases
• Vaccinology

Background:

• The efficacy of coronavirus disease 2019 (COVID-19) booster vaccinations in patients with B-cell non-Hodgkin's lymphoma (B-NHL) is less understood compared to healthy individuals.
• Existing research has not clearly defined how histological subtype or treatment status influences COVID-19 booster vaccine effectiveness in B-NHL patients.
• Limited data exists on breakthrough infections following COVID-19 booster vaccination in this immunocompromised population, especially during the Omicron variant era.

Purpose of the Study:

• To evaluate the effectiveness of the first COVID-19 booster vaccination in patients diagnosed with B-cell non-Hodgkin's lymphoma.
• To analyze the clinical characteristics and outcomes of breakthrough COVID-19 infections occurring after booster vaccination in B-NHL patients.
• To investigate the impact of histological subtype and treatment status on the immune response to COVID-19 booster vaccines in B-NHL.

Main Methods:

• Classified B-NHL patients into aggressive and indolent histological subtypes.
• Subdivided patients based on their treatment status with anticancer drugs at the time of the first COVID-19 booster vaccination.
• Examined clinical characteristics and outcomes of patients who experienced breakthrough infections post-booster vaccination, focusing on the Omicron variant.

Main Results:

• Booster vaccine effectiveness in B-NHL patients significantly depended on their treatment status at the time of vaccination.
• Patients over one year post-anticancer treatment showed booster effectiveness comparable to healthy controls, irrespective of lymphoma subtype.
• A poorer booster effect was observed in B-NHL patients undergoing active anticancer treatment; however, breakthrough infections (10.3%) were predominantly mild (81.8%).

Conclusions:

• COVID-19 mRNA booster vaccination effectiveness in B-cell non-Hodgkin's lymphoma patients is highly dependent on their recent treatment history.
• While some B-NHL patients exhibit a diminished response, booster vaccination may still mitigate the severity of Omicron variant COVID-19 infections.
• Further research is warranted to optimize vaccination strategies for B-NHL patients to enhance protection against SARS-CoV-2 variants.